![]() ![]() A description of these patients is below. ![]() Initial diagnosis was concerning for metastasis however, further investigation revealed that these patients had received COVID-19 vaccinations prior to imaging. In our center, we have observed unilateral axillary lymphadenopathy in five patients using different imaging modalities including PET/CT, MRI and ultrasonography. In the above vaccine trials, abnormal lymphadenopathy was reported based on physical examination rather than using imaging. In the Pfizer-BioNTech COVID-19 vaccine trial, the rate of ipsilateral axillary and supraclavicular lymphadenopathy was reported to be 0.3% among vaccine recipients versus <0.1% among placebo group ( 5). In the Moderna cohort, clinically detected axillary and supraclavicular lymphadenopathy was reported in 1.1% of study participants within 2-4 days after vaccination, as an unsolicited adverse event ( 4). Ipsilateral axillary swelling/tenderness was the second most frequently reported local reaction to the Moderna COVID-19 vaccine, occurring in 11.6% and 16.0% of recipients following first and second dose respectively. In clinical studies, axillary lymphadenopathy was reported on the ipsilateral injection side ( 4, 5). In conjunction with the rapid administration of these vaccines, we have started to observe secondary effects on diagnostic imaging. As of February 6, 2021, about 28.9 million people in the United States had received one or more vaccine doses. The United States Food and Drug Administration issued emergency use authorization for two vaccines, Pfizer-BioNTech and Moderna COVID-19 vaccines, to help decrease COVID-19 infection and death in December 2020. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |